Shuttle Pharmaceuticals Holdings, Inc. - SHPH STOCK NEWS

Shuttle Pharmaceuticals Holdings, Inc. provides a corporate update, including progress on their lead drug candidate Ropidoxuridine. They are on track to commence Phase II clinical study in Q4 2023 and have completed the initial manufacturing campaign for the drug. They have also received FDA approval for a Type B pre-IND meeting. The company has moved into new laboratory and office space to accelerate development and diagnostic capabilities. Q2 2023 operating expenses totaled $1.5 million and cash balance was $8.4 million.

Shuttle Pharmaceuticals announces successful completion of initial manufacturing campaign for Ropidoxuridine API for upcoming Phase II clinical trial in brain cancer patients undergoing radiation therapy. Company also receives approval for Type B pre-IND meeting with FDA.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced a research agreement with Georgetown University to evaluate its lead HDAC6 inhibitor candidate, SP-2-225. The collaboration will focus on the anti-tumor effects of SP-2-225 in combination with radiation therapy (RT) using a breast cancer model. The research aims to support IND-enabling studies in 2023 with plans for a Phase I clinical trial in 2024. SHPH's pipeline includes Ropidoxuridine, aimed at enhancing cancer cell sensitivity to RT, which is progressing towards Phase II testing in brain cancer patients. This partnership underscores SHPH's commitment to improving cancer treatment outcomes.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) reported a corporate update on March 15, 2023, in conjunction with its Annual Report on Form 10-K for the fiscal year ending December 31, 2022. The company raised $11.5 million through its IPO and $4.3 million through a private placement. It is preparing for a Phase II clinical trial of its lead drug candidate, Ropidoxuridine, aimed at enhancing outcomes for glioblastoma patients undergoing radiation therapy. With a cash balance of $8.4 million as of December 31, 2022, and recent funding, Shuttle anticipates sufficient capital to support operations through Q4 2025.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced a partnership with the University of Iowa Pharmaceuticals for the formulation development and clinical batch manufacturing of Ropidoxuridine. This step is crucial for their upcoming Phase II clinical trial aimed at glioblastoma treatment, expected to be submitted to the FDA by Q2 2023. The company has manufactured approximately 10,000 capsules for the trial, working alongside TCG GreenChem, Inc. With over 800,000 patients annually receiving radiation therapy in the U.S., Shuttle's focus on radiation sensitizers positions it to address significant market needs in oncology.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced that it will lease new laboratory and office space in Gaithersburg, Maryland, starting in June 2023. This expansion aims to support the development of its lead drug candidate, Ropidoxuridine, which is designed to sensitize cancer cells during radiation therapy. The company is advancing a Phase II clinical trial for brain cancer patients and plans to submit an Investigational New Drug application to the FDA by Q2 2023. Shuttle's platform seeks to address clinical needs for radiation sensitizers and has received NIH funding for related research.

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH), a pharmaceutical company dedicated to enhancing cancer treatment outcomes, announced that CEO Anatoly Dritschilo will present at the Lytham Partners Investor Select Conference on January 31, 2023. This virtual event will include one-on-one meetings with investors, providing a platform for discussion on the company's mission to improve radiation therapy efficacy while minimizing side effects. A webcast of the presentation will be available at 9:00 AM ET on the same day, with a replay option afterward. For more details, visit their website.